首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3784786篇
  免费   325270篇
  国内免费   14047篇
耳鼻咽喉   51723篇
儿科学   120682篇
妇产科学   99024篇
基础医学   592365篇
口腔科学   104781篇
临床医学   339993篇
内科学   677981篇
皮肤病学   96936篇
神经病学   325581篇
特种医学   151690篇
外国民族医学   503篇
外科学   585016篇
综合类   114863篇
现状与发展   24篇
一般理论   2487篇
预防医学   314211篇
眼科学   87739篇
药学   266436篇
  19篇
中国医学   10303篇
肿瘤学   181746篇
  2021年   55954篇
  2020年   35763篇
  2019年   58875篇
  2018年   72714篇
  2017年   55182篇
  2016年   61220篇
  2015年   75061篇
  2014年   109808篇
  2013年   175501篇
  2012年   104825篇
  2011年   106204篇
  2010年   120690篇
  2009年   124612篇
  2008年   93422篇
  2007年   97554篇
  2006年   107825篇
  2005年   103057篇
  2004年   105213篇
  2003年   95394篇
  2002年   84921篇
  2001年   121434篇
  2000年   115579篇
  1999年   112243篇
  1998年   67684篇
  1997年   65118篇
  1996年   62998篇
  1995年   58600篇
  1994年   52697篇
  1993年   49218篇
  1992年   83218篇
  1991年   79676篇
  1990年   76151篇
  1989年   74834篇
  1988年   69639篇
  1987年   68352篇
  1986年   65095篇
  1985年   64993篇
  1984年   56759篇
  1983年   51449篇
  1982年   44939篇
  1981年   42109篇
  1980年   39660篇
  1979年   49070篇
  1978年   41064篇
  1977年   36893篇
  1976年   34184篇
  1975年   32951篇
  1974年   35623篇
  1973年   34261篇
  1972年   31755篇
排序方式: 共有10000条查询结果,搜索用时 453 毫秒
41.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome.  相似文献   
42.
43.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy  相似文献   
44.
45.
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer  相似文献   
46.
47.
48.
49.
50.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号